PMV Pharmaceuticals, Inc. $PMVP Shares Purchased by BML Capital Management LLC

BML Capital Management LLC lifted its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 37.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,330,000 shares of the company’s stock after acquiring an additional 2,000,000 shares during the period. PMV Pharmaceuticals makes up approximately 6.5% of BML Capital Management LLC’s portfolio, making the stock its 4th biggest position. BML Capital Management LLC owned approximately 13.71% of PMV Pharmaceuticals worth $12,241,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Eversept Partners LP acquired a new stake in PMV Pharmaceuticals during the first quarter worth approximately $2,912,000. BlackRock Inc. bought a new stake in PMV Pharmaceuticals in the second quarter worth approximately $1,233,000. Stonepine Capital Management LLC acquired a new position in PMV Pharmaceuticals in the second quarter valued at approximately $718,355. Bank of America Corp DE acquired a new position in PMV Pharmaceuticals in the second quarter valued at approximately $322,000. Finally, Rangeley Capital LLC lifted its stake in PMV Pharmaceuticals by 46.9% in the first quarter. Rangeley Capital LLC now owns 66,846 shares of the company’s stock valued at $83,000 after buying an additional 21,346 shares during the period. 90.20% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on PMVP shares. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of PMV Pharmaceuticals in a report on Friday, September 4th. Weiss Ratings upgraded shares of PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Finally, Wall Street Zen downgraded shares of PMV Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $4.33.

PMV Pharmaceuticals Trading Up 5.0%

Shares of NASDAQ PMVP opened at $1.27 on Friday. The firm’s 50-day moving average price is $1.39 and its 200-day moving average price is $1.31. PMV Pharmaceuticals, Inc. has a 1-year low of $1.02 and a 1-year high of $1.91. The firm has a market capitalization of $67.89 million, a P/E ratio of -0.82 and a beta of 1.52.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Tuesday, November 10th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.18). Equities research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.36 EPS for the current year.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals is a biopharmaceutical company focused on developing precision cancer treatments. Its research centers on the tumor-suppressor protein p53, which is altered in many cancers, with the goal of restoring its function through targeted medicines. The company’s lead investigational drug, rezatapopt (also known as PC14586), is designed to reactivate a specific mutated form of p53 called Y220C. PMV has studied the drug in clinical trials for patients with advanced solid tumors carrying that mutation.